Previous 10 | Next 10 |
home / stock / wuxay / wuxay news
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility PR Newswire New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI , Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leadin...
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers PR Newswire SHANGHAI , Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new steri...
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware PR Newswire MIDDLETOWN, Del. , Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is please...
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology PR Newswire PHILADELPHIA , Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Jans...
WuXi AppTec Reports Record First-Half Results in 2022 PR Newswire Revenue Up 68.5% Year-Over-Year to RMB17,756 Million Net Profit Attributable to Owners of the Company Up 73.3% Year-Over-Year to RMB4,636 Million Diluted Earnings Per Share (E...
Frontera Therapeutics completed a $160 million Series B funding to support its AAV programs. Merck KGaA announced its Uptune program will back Asia startup companies with up to €100,000 each to advance their projects into proof-of-concept studies. Shanghai Antengene will co...
Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility PR Newswire Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announc...
Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989. Emerging Markets (EMs) declined sharply, primarily due to the collapse in Russian equities brought about by economic sanctions against Russia because of i...
WuXi AppTec Reports Record First-Quarter In 2022 PR Newswire Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million Diluted Earnings Per Share (EPS)...
News, Short Squeeze, Breakout and More Instantly...
Wuxi AppTec Co. Ltd. ADR Company Name:
WUXAY Stock Symbol:
OTCMKTS Market:
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations PR Newswire Revenue Reached RMB7,982 Million ; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...